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The skeleton is the most frequently affect-
ed organ in metastatic breast cancer [1]. 
Up to 2.6 % of all breast cancer patients 
have bone metastases at the initial diag-
nosis and up to 15 % will develop bone me-
tastases within 15 years [2, 3].
Drug-resistant pain, pathological frac-
tures, and neurological complications are 
the most common consequences, induc-
ing significant morbidity and impairment 
of quality of life. The treatment of bone 
metastases requires a multidisciplinary 
approach with surgical, pain therapeuti-
cal, oncological, and radiotherapeutical 
care.
Indications for radiotherapy (RT) are 
pain, existing or impending instability, 
neurological symptoms due to compres-
sion of the spinal cord, or previous surgi-
cal intervention [4]. RT offers pain relief 
in 50–80 % of patients. The benefit of RT 
concerning pain and recalcification of os-
teolytic metastases may be greater when 
the therapy is combined with concomitant 
administration of bisphosphonates [1].
Orthopedic thoracic corsets are used to 
prevent vertebral fractures and consecu-
tive spinal cord compression. Immobiliza-
tion for pain and suspected instability are 
consequences of spinal metastases. The 
use of a validated scoring system to assess 
the stability of spinal bone metastases may 
prevent physicians from overdiagnosis of 
instability and, thus, improve the quality 
of life in palliative-stage patients.
The aim of this retrospective analysis 
of breast cancer patients with bone metas-
tases was to systematically assess the bone 
lesions in terms of stability, fractures pri-
or to and following RT, survival, and pre-
dictive factors for stability.
Patients and methods
This analysis was based on 115 patients, 
whose 157 osseous lesions were treated by 
RT for metastases of the vertebral column 
due to histologically diagnosed breast 
carcinoma from January 2000 to January 
2012. Patients underwent regular follow-
up examinations including computer to-
mography (CT) imaging.
Patients with osteolytic metastases, 
localization in the thoracic and lumbar 
spine, and a minimum duration of fol-
low-up treatment of 6 months were in-
cluded in this retrospective analysis. Pa-
tient data were taken from a cancer reg-
istry. Patients who were irradiated in sev-
eral regions were regarded separately for 
each region in our analysis. Within each 
region, the most severe metastasis accord-
ing to the Taneichi score was included in 
the analysis [6]. Accordingly, 115 patients 
with 157 irradiated regions, including 480 
vertebral bodies in the thoracic and lum-
bar spine, were evaluated. For each region 
one metastasis with the highest probabil-
ity of collapse according to the Taneichi 
score was chosen for the examination.
All patients were female. The most fre-
quent histological type was invasive duc-
tal carcinoma (79 %). The Karnofsky Per-
formance Status Scale (KPS) was used to 
assess performance status [5]. The diag-
nosis of bone metastasis was made on the 
basis of the CT or magnetic resonance 
imaging (MRI) findings or bone scintig-
raphy investigations. The patient charac-
teristics are summarized in . Table 1.
The stability of each affected vertebral 
body was assessed according to the Ta-
neichi score on the basis of the CT image 
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Table 1 Patient characteristics
n %
Age at radiotherapy (years)







Invasive ductal 124 79
Invasive lobular 31 20
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recorded before RT to plan treatment and 
also in the follow-up stage 3 and 6 months 
after radiotherapy [6].
The osteolytic metastases were rated 
on a scale from A to G. Subtypes A to C 
were defined as stable, subtypes D to G as 
unstable (. Fig. 1).
Most patients received addition-
al chemotherapy, endocrine therapy, or 
bisphosphonates before and after RT. 
After RT, 91 % of the lesions were treat-
ed with bisphosphonates (. Table 2), and 
61 % of the patients were equipped with 
an orthopedic thoracic corset.
This study was approved by the insti-
tutional ethics committee on 22 October 
2012 (nr. S-513/2012).
Radiotherapy
RT was applied for instability in 67 and 
52 % of patients due to pain, when re-
garding the documented indication for 
therapy. The treatment was carried out 
at the department of radiation oncology. 
RT was planned using virtual simulation 
based on CT scans, and was performed 
over a dorsal photon field with energy of 
6 MV. The planning target volume (PTV) 
covered the vertebral body affected as well 
as bodies immediately above and below. 
The most frequent radiation schedule 
was 10 fractions of 3 Gy in 57 % of cas-
es (. Table 2). The fractionation sched-
ule was selected individually for each pa-
tient, depending on the patient’s gener-
al state of health, the current staging, re-
sponse to current therapy, and the respec-
tive prognosis.
Statistical analysis
The empirical distribution of continu-
ous variables is described by the number 
of observations, mean and standard devi-
ation; the description of categorical vari-
Fig. 1 8 Applied score for osteolytic metastases of the thoracic and lumbar spine [6]
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ables includes the number and percentage 
of patients belonging to the relevant cat-
egories.
The univariate chi-square test was used 
to evaluate the prognostic factors for the 
endpoint stabilization of spinal metas-
tases for the factors age, KPS, histology, 
number of metastasis (1 vs. > 1), irradiat-
ed area (thoracic vs. lumbar spine), hor-
mone receptor status (positive vs. nega-
tive), overall dose, and concomitant thera-
py (chemotherapy, hormone drug therapy, 
bisphosphonates) separately for the peri-
od within 6 months before and after RT.
Survival times are presented graphical-
ly, using the Kaplan–Meier method. Pa-
tients who were lost to follow-up were in-
cluded in the statistics as censored obser-
vations.
“Bone survival” was defined as the 
time from the first diagnosed spinal me-
tastases to death. Overall survival was de-
fined as the time from the initial diagno-
sis of breast cancer to death.
For the distribution of Taneichi score 
subtypes before and 6 months after RT, 
the Bowker test was used. Kappa statistics 
were calculated to detect possible asym-
metry in the distribution of the Taneichi 
score over time.
Overall survival and bone survival 
were calculated for subgroups divided by 
the number of irradiated metastases, to 
account for the acceptance that patients 
with one metastasis requiring treatment 
will have a better prognosis than those 
with multiple metastases.
Results
The median follow-up of all patients was 
16.7 months (mean 19.9, range 0.4–74.7 
months). Thirty patients (19 %) died dur-
ing follow-up. Seventy patients (61 %) had 
only bone metastases, 45 patients (39 %) 
had metastases in other distant organs 
such as t5he liver (n = 22), lung (n = 19), 
and brain (n = 11).
Before RT, 46 % (n = 72) of the lesions 
were classified as stable according to the 
Taneichi score. Of the stable bone metas-
tases, none were rated unstable in the fur-
ther course of study (p < 0.001, McNemar 
test).
Of the 85 patients (54 %) in whom the 
metastases were classified as unstable pri-
or to RT, 24 patients were classified as sta-
ble after 3 months, and 35 patients stable 
after 6 months. This means that in total, 
61 and 68 % of the bone metastases were 
stable after 3 and 6 months, respectively 
(. Table 3).
The evaluation of the distribution of 
subtypes A to G showed a major change 
in the direction of improvement over 
the course of time. Improvement in the 
score occurred in 61 % patients (n = 95). 
Improvement of stability was detect-
ed in 22 % (n = 35) of all cases. This cor-
responds to an improvement of stabili-
ty in 45 % of all unstable lesions (n = 85). 
Deterioration of stability was detected 
in 2 % of cases (n = 3). The Bowker test 
shows the distribution pattern of the sub-
types according to the Taneichi score pri-
or to and 6 months after RT. Asymmetry 
was apparent (p = 0.0001) and the corre-
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Abstract
Purpose. This retrospective analysis was per-
formed to evaluate osteolytic bone lesions 
of breast cancer in the thoracic and lumbar 
spine after radiotherapy (RT) in terms of sta-
bility using a validated scoring system.
Methods. The stability of 157 osteolytic me-
tastases, treated from January 2000 to Jan-
uary 2012, in 115 patients with breast can-
cer was evaluated retrospectively using the 
Taneichi score. Predictive factors for stabili-
ty were analyzed and survival rates were cal-
culated.
Results. Eighty-five (54 %) lesions were clas-
sified as unstable prior to RT. After 3 and 6 
months, 109 (70 %) and 124 (79 %) lesions, 
respectively, were classified as stable. Thirty 
fractures were detected prior to RT, and after 
RT seven cases (4.5 %) with pathologic frac-
tures were found within 6 months. None of 
the examined predictive factors showed sig-
nificant correlation with stability 6 months 
after RT. After a median follow-up of 16.7 
months, Kaplan–Meier estimates revealed an 
overall survival of 83 % after 5 years.
Conclusion. The majority of patients showed 
an improved or unchanged stability of the in-
volved vertebral bodies after 6 months. The 
patients showed only minor cancer-relat-
ed morbidity during follow-up and reached 
comparably high survival rates.
Keywords
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Stability · Fracture
Stabilität von Wirbelsäulenmetastasen bei Brustkrebs nach 
Radiotherapie. Eine retrospektive Analyse von 157 Fällen
Zusammenfassung
Hintergrund. Die retrospektive Analyse 
untersuchte osteolytische Knochenmetasta-
sen von Patienten mit Mammakarzinom der 
thorakalen und lumbalen Wirbelsäule nach 
Radiotherapie (RT) hinsichtlich Stabilität an-
hand eines validierten Scores.
Methoden. Die Stabilität von 157 osteoly-
tischen Metastasen bei 115 Patienten mit 
Brustkrebs, behandelt von Januar 2000 bis Ja-
nuar 2012, wurde retrospektiv anhand des 
Taneichi-Scores evaluiert. Prognostische Fak-
toren bezüglich Stabilität und Überlebensra-
ten wurden analysiert.
Ergebnisse. Vor RT wurden 85 Läsionen 
(54 %) als instabil gewertet. Nach 3 und 6 Mo-
naten wurden 109 (70 %) und 124 (79 %) Lä-
sionen als stabil klassifiziert. Vor RT wurden 
30 Frakturen gefunden, nach RT zeigten sich 
7 weitere (4,5 %) pathologische Frakturen. 
Kein prognostischer Faktor hatte signifikan-
ten Einfluss auf die Stabilität 6 Monate nach 
RT. Nach einer Beobachtungszeit von me-
dian 16,5 Monaten ergab sich aus der Kaplan-
Meier-Berechnung eine Gesamtüberlebens-
zeit von 83 % nach 5 Jahren.
Schlussfolgerung. Die Mehrheit der Patien-
ten zeigte eine verbesserte oder konstante 
Stabilität der befallenen Wirbelkörper nach 6 
Monaten. Die analysierten Patienten zeigten 
nur geringe tumorassoziierte Einschränkun-
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lation (weighted kappa = 0.67) was good 
(. Table 4).
Before RT, 30 patients had patholog-
ical fractures within the irradiated re-
gion. During the follow-up, in seven cas-
es (4.5 %) new fractures were found, of 
which all but one had been evaluated as 
unstable before RT (n = 6).
Using fractionation patterns with 
overall doses of 30–40 Gy, there was no 
correlation between overall dose and sta-
bility after RT (p = 0.12).
Furthermore, there was no signifi-
cant correlation in the univariate analy-
sis between stability after RT and the po-
tential predictive factors such as bisphos-
phonates, chemotherapy, and hormone 
therapy before and after RT. Further fac-
tors tested in the univariate analysis were 
age, KPS, hormone receptor status, his-
tology, and location of the examined me-
tastasis (lumbar spine vs. thoracic spine; 
. Table 3).
Overall survival was 83 % at 5 years for 
all patients (. Fig. 2). The 5-year survival 
rate for patients with one treated metasta-
sis and more than one metastasis was 88 
and 79 %, respectively. Bone survival for 
all patients was 69 % (. Fig. 3), and 74 and 
59 % for patients with one and more than 
one treated metastasis, respectively.
The difference between the subgroups 
of patients with one and more than one 
metastasis in both measured periods, 
overall survival and bone survival, was 
not significant, with a p value of 0.12 and 
0.078, respectively, in the log-rank test.
Discussion
Besides pain, the reduced stability is the 
most frequent reason for radiation of 
bone metastases. The scoring system by 
Taneichi et al. classifies osteolytic metas-
tases of the thoracic and lumbar spine by 
risk factors such as tumor size and in-
volvement of costovertebral joints for the 
thoracic region (Th 1 to 10) and by tumor 
size and destruction of the pedicles for the 
lumbar region (Th11, Th12, and all lum-
bar vertebrae). Posterior elements seem 
to have a major impact on stabilization, 
which was found in biometrical models 
of the thoracic and lumbar spine verte-
brae [7–9].
Before RT, 46 % of the lesions (n = 72) 
were classified as stable, and after 6 
months 70 % (n = 110) were stable. Pa-
tients benefit from stabilized metastases 
in daily life, as soon as they can omit their 
corset.
In patients who were treated before the 
validated score was introduced in the fa-
cility in 2011, stability of osteolytic bone 
lesions was estimated on the basis of sev-
eral factors such as involvement of the 
rear edge at the vertebral foramen and 
pain. According to the documentation, 
67 % of the irradiated metastases were un-
stable. Applying the validated score ret-
rospectively, 54 % of the metastases were 
Table 3 Results of prognostic factors related to stability
n %
Stability
Prior to RT 72 54
3 months after RT 96 61






Number of metastases (1 vs. > 1) 0.27
Area (thoracic vs. lumbar spine) 0.97





Therapy within 1 year before RT
Chemotherapy (yes vs. no) 0.90
Hormone therapy (yes vs. no) 0.12
Bisphosphonates (yes vs. no) 0.62
Therapy after RT
Chemotherapy (yes vs. no) 0.21
Hormone therapy (yes vs. no) 0.88
Bisphosphonates (yes vs. no) 0.36
Table 4 Distribution of subtypes A to G 
over the course of time (0–6 months)
Bowker test
6 months after RT
Prior 
to RT
A B C D E F G
A 25 1 0 1 0 0 0
B 11 17 0 0 0 0 0
C 4 2 9 0 2 0 0
D 5 2 4 12 0 0 0
E 8 2 0 2 20 0 0
F 10 2 3 0 2 10 0
G 2 0 0 0 0 1 0
Table 2 Therapy characteristics
Radiotherapy (RT) n %
10 × 3 Gy 89 57
14 × 2.5 Gy 25 16













Endocrine therapy 109 69
Bisphosphonates 143 91
Stability
Stable prior to RT 72 46
Stable 3 months 
after RT
97 62
Stable 6 months 
after RT
107 68
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rated unstable. The difference is result of 
the changed criteria.
Fractures were detected in 30 lesions. 
The follow-up examinations revealed sev-
en patients with progressive bone destruc-
tion or new fracture.
According to the literature, symptom-
atic spinal cord compression in patients 
with bone metastases can be expected 
in 10 % of all cases [4]. The patients in-
cluded in our analyses showed less fre-
quent and less severe neurologic deficits. 
The reasons might be a preference of sur-
gical treatment for certain patients’ met-
astatic spinal cord compression and the 
poor prognosis of patients with inopera-
ble compression, leading to their disqual-
ification for this analysis due to a lack of 
follow-up examinations. In our analy-
sis three patients had existing symptom-
atic spinal cord compression. A further 
four patients revealed less severe deficits, 
such as incomplete paralyses or disorders 
in the function of the bowl or bladder due 
to metastases in the further course of the 
disease and more than 6 months after RT. 
Complete paraplegia developed in one pa-
tient several years after RT.
The rarity of neurological signs might 
be caused by the preference of surgery in 
these patients, as it offers immediate de-
compression of the spinal cord and sta-
bilization [10]. In the analyzed cases, RT 
was preferably applied to prevent neuro-
logic symptoms and pain caused by col-
lapsing metastases.
All examined factors such as age, KPS, 
hormone receptor status, histology of the 
primary tumor, and location of the exam-
ined metastasis failed to show significant 
influence on the probability for restabili-
zation after RT. The concomitant thera-
py with hormone therapy, chemotherapy, 
and bisphosphonates therapy also did not 
show any favorable influence in our anal-
ysis. Similar results were already observed 
in an analysis of bone metastases in lung 
cancer patients [11].
The predominately used dose sched-
ules for the analyzed cases were 10 frac-
tions of 3 Gy, 14 fractions of2.5 Gy, and 
20 fractions of 2 Gy. As suggested by cur-
rent guidelines, the fractionation schemes 
were individually selected regarding mul-
tiple factors such as prognosis and gen-
eral state [11]. One can assume that pro-
longed radiation has a longer lasting effect 
on bone metastases and a minor proba-
bility of in-field recurrences. Considering 
the available data from the literature, there 
seem to be few distinctions between the 
applied fractionations [1, 4]. The analysis 
consistently showed no significant differ-
ence in the fractionation schedules used 
in our study.
Remarkably, this analysis focused on 
stabilization of irradiated metastasis with-
in 6 months. This implies that there might 
be limitations, when examining the influ-
ence of systemic or long-term therapies.
Improvements in the therapy of bone 
metastases were accomplished by con-
comitant drug therapy such as bisphos-
phonates [12]. Several trials showed that 
concomitant bisphosphonates therapy 
seems to be secure and is assumed to sup-
port recalcification. Nevertheless, there 
is no evidence from controlled prospec-
tive trials of the superiority of a combined 
therapy compared with RT alone [1]. One 
recent similar analysis, examining predic-
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Fig. 3 8 Bone survival
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metastasized breast cancer patients, sug-
gests that bisphosphonate treatment 
might be linked to longer overall surviv-
al. According to this report, patients re-
ceiving hormone therapy or chemother-
apy had no significant survival benefit 
[13]. Further reports did not find a ben-
efit when comparing the hormone recep-
tor status with the probability for skele-
tal complications [14]. In our analysis we 
could not detect a benefit for hormone or 
chemotherapy after RT concerning the 
endpoint stabilization.
The median overall survival for meta-
static breast cancer is long (several years) 
when compared with other tumors such 
as lung cancer [15–17]. In our analysis, we 
measured a survival of 82 % after 5 years, 
which is longer than the overall survival 
measured in similar studies [10]. The ex-
tended survival might be a manifestation 
of the selection criteria, by only including 
patients with at least 6 months of follow-
up. This is also illustrated by the high ini-
tial KPS with median value of 80.
Prolonged survival is associated with 
absent extraskeletal metastases, which 
was the case in most patients. Sung et al. 
reported a median survival after the di-
agnosis of bone-only metastases of 75 
months [95 % confidence interval (CI), 
38.6–71.9] with increased survival of de 
novo bone metastases [13]. The num-
ber of patients with de novo and bone-
only metastases in our analyses was high 
at 45 %. The comparatively high estimat-
ed survival rates emphasize the need for 
a palliative therapy that is not restricted 
to pain relief but preserves the patient’s 
physical autonomy.
Conclusion
The use of a systematic radiological scor-
ing system to classify osteolytic metas-
tases of the vertebral column was shown 
to be practicable for patients with me-
tastasized breast cancer in the follow-up 
period after RT, and should be applied 
in daily routine. The majority of patients 
showed an improved or unchanged sta-
bility of their involved vertebral bodies 
after 6 months.
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